Benzinga's Microcap Movers for Friday June 15, 2012
CORRECTION: The earlier reports of a $100M share buyback for ReneSola were not correct. The share buyback was for JA Solar (NASDAQ: JASO).
Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:
Anthera Pharmaceuticals (NASDAQ: ANTH), the Hayward, CA biopharmaceutical company, rose 22.87% Friday on 3 times the average daily volume.
On Wednesday, Anthera was initiated at JMP Securities with a Market Outperform and a $4 price target. A positive Seeking Alpha article appeared on Friday, discussing the company's Lupus drug Blisibimod.
Anthera Pharmaceuticals closed at $2.74 on Friday.
Shares of ReneSola (NYSE: SOL), the China-based solar wafer producer, rose 12.85% Friday on average volume.
ReneSola closed at $1.65 on Friday, well off its 52-week high of $5.36.
Shares of Hanwha SolarOne (NASDAQ: HSOL), the Korean-owned and China-based manufacturer of solar energy products, rose 24.15% Friday on 3 times the average daily volume.
On Thursday Hanwha SolarOne announced an agreement with Italian business association Assoimprese, which represents 600,000 small and medium-sized businesses.
Assoimprese has signed a two-year contract with Hanwha SolarOne which is expected to be extended in the future. As a first step Assoimprese has purchased poly-crystalline Hanwha SolarOne modules with a total volume of 47 Megawatt for 2012. The installers who are members of Assoimprese can now profit from the association's expertise as well as special rates and buy the preselected modules from the association directly instead of purchasing through a distributor.
Hanwha SolarOne closed at $1.18 on Friday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.